Development new immunotherapy for pediatric cancer using human iPSCs

• Project/Area Number: 26461583
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Osaka University
• Principal Investigator: Miyamura Takako 大阪大学, 医学系研究科, 助教 (20379796)
• Co-Investigator(Kenkyū-buntansha): 橋井 佳子 大阪大学, 医学系研究科, 講師 (60343258) ; 北畠 康司 大阪大学, 医学部附属病院, 講師 (80506494)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: iPS細胞 / ガン免疫療法 / がんワクチン療法 / ゲノム編集 / 免疫療法 / がん免疫療法 / ゲノム編集技術

Outline of Final Research Achievements

We aimed to develop more efficient immunotherapy for pediatric cancer, using WT1 cancer vaccines and human iPSCs. We established the method to generate iPSCs more efficiently using Sendai virus.In addition, we developed oral cancer vaccine method using Bifidobacterium longum displaying WT1 protein.

Research Products

• [Journal Article] Systematic cellular disease models reveal synergistic interactions of trisomy 21 and GATA1 mutations in hematopoietic abnormalities (2016)
  • Author(s): K. Banno, S. Omori, K. Hirata, N. Nawa, N. Nakagawa, K. Nishimura, M. Ohtaka, M. Nakanishi, T. Sakuma, T. Yamamoto, T. Toki, E. Ito, T. Yamamoto, C. Kokubu, J. Takeda, H. Taniguchi, H. Arahori, K. Wada, Y. Kitabatake and K. Ozono
  • Journal Title: Cell Rep. Volume: 15 Pages: 1228-1241
  • DOI: 10.1016/j.celrep.2016.04.031
  • NAID: 120007135439
  • Peer Reviewed / Open Access / Acknowledgement Compliant